摘要
目的:观察疏血通联合脑蛋白水解物治疗急性脑梗死的临床疗效。方法:将108例急性脑梗死患者随机分为治疗组和对照组各54例。两组患者均按照急性脑梗死常规治疗方案进行干预,对照组在常规治疗方案的基础上加用脑蛋白水解物静脉滴注,治疗组在对照组治疗方案的基础上加用疏血通注射液静脉滴注。治疗2周后,对比两组患者的临床疗效及神经功能缺损评分(NIHSS)的变化情况;并观察治疗过程中不良反应的发生情况。结果:愈显率治疗组为81.48%,对照组为61.11%,组间比较,差异有统计学意义(P<0.05);两组患者治疗第7天和第14天的NIHSS评分治疗前后组内比较及治疗后组间比较,差异均有统计学意义(P<0.05)。结论:疏血通联合脑蛋白水解物可改善急性脑梗死患者的临床疗效,且具有良好的安全性,可资临床借鉴。
Objective： To observe the clinical efficacy of Shuxuetong combined with cerebroprotein hydrolysate in the treatment of acute cerebral infarction. Methods： A total of 108 patients with acute cerebral infarction were randomly and equally divided into treatment group and control group. The control group was given cerebroprotein hydrolysate by intravenous drip in addition to the conventional treatment of acute cerebral infarction; the treatment group was given Shuxuetong injection by intravenous drip in addition to the treatment for the control group. After two weeks of treatment,the two groups were compared in terms of treatment outcome and National Institutes of Health Stroke Scale（ NIHSS） score. The incidence of adverse events was determined. Results： The treatment group had a significantly higher cure and marked response rate than the control group（ 81. 48% vs 61. 11%,P 0. 05）. On days 7 and 14 of treatment,both groups showed significant improvements in NIHSS score（ P 0. 05）,and this score showed significant differences between the two groups（ P 0. 05）. Conclusion： Shuxuetong combined with cerebroprotein hydrolysate has improved efficacy in the treatment of acute cerebral infarction and has high safety. This therapy holds promise for clinical application.
出处
《湖南中医杂志》
2016年第3期3-5,共3页
Hunan Journal of Traditional Chinese Medicine
关键词
急性脑梗死
疏血通
脑蛋白水解物
acute cerebral infarction
Shuxuetong
cerebroprotein hydrolysate
